TABLE TRAC INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that TABLE TRAC INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.05M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $11.16M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $9.49M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $11.06M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $6.97M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $4.40M | Mar 28, 2022 |
| FY2020 | Sep 30, 2020 | $1.19M | Mar 31, 2021 |
| FY2020 | Jun 30, 2020 | $1.13M | Mar 31, 2021 |
| FY2020 | Mar 31, 2020 | $1.13M | Mar 31, 2021 |
| FY2020 | Dec 31, 2019 | $7.91M | Mar 31, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.16M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $7.89M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $7.05M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $6.95M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $5.07M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $3.33M | Mar 28, 2022 |
| FY2020 | Sep 30, 2020 | $874.2K | Mar 31, 2021 |
| FY2020 | Jun 30, 2020 | $1.04M | Mar 31, 2021 |
| FY2020 | Mar 31, 2020 | $898.5K | Mar 31, 2021 |
| FY2020 | Dec 31, 2019 | $5.45M | Mar 31, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.63M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $1.58M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $1.61M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $1.62M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $1.71M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $306.9K | Mar 28, 2022 |
| FY2020 | Sep 30, 2020 | $29.5K | Mar 31, 2021 |
| FY2020 | Jun 30, 2020 | $81.6K | Mar 31, 2021 |
| FY2020 | Mar 31, 2020 | ($10.2K) | Mar 31, 2021 |
| FY2020 | Dec 31, 2019 | $805.3K | Mar 31, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.60M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $1.72M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $1.68M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $2.02M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $1.51M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | ($343.0K) | Mar 28, 2022 |
| FY2020 | Sep 30, 2020 | $30.4K | Mar 31, 2021 |
| FY2020 | Jun 30, 2020 | $60.5K | Mar 31, 2021 |
| FY2020 | Mar 31, 2020 | ($39.3K) | Mar 31, 2021 |
| FY2020 | Dec 31, 2019 | $922.8K | Mar 31, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $771.1K | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $243.4K | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $208.3K | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $190.7K | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $469.6K | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $283.4K | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $272.2K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $118.8K | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $46.7K | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $76.2K | Mar 30, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.55M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $6.18M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $5.37M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $4.93M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $3.56M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $3.67M | Mar 28, 2022 |
| FY2020 | Sep 30, 2020 | $843.8K | Mar 31, 2021 |
| FY2020 | Jun 30, 2020 | $975.3K | Mar 31, 2021 |
| FY2020 | Mar 31, 2020 | $937.8K | Mar 31, 2021 |
| FY2020 | Dec 31, 2019 | $4.53M | Mar 31, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.81M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $2.02M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $394.9K | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | ($63.9K) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $2.80M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | ($5.3K) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $55.1K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $138.8K | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $1.32M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | ($141.9K) | Mar 30, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $31.1K | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $129.1K | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $39.4K | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Mar 29, 2024 |
| FY2020 | Dec 31, 2020 | $0 | Mar 31, 2021 |
| FY2020 | Dec 31, 2019 | $35.4K | Mar 31, 2021 |
| FY2013 | Dec 31, 2013 | $10.9K | Mar 26, 2014 |
| FY2013 | Dec 31, 2012 | $10.9K | Mar 26, 2014 |
| FY2012 | Dec 31, 2011 | $0 | Mar 28, 2013 |
| FY2011 | Dec 31, 2010 | $31.8K | Mar 29, 2012 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.37M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $13.52M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $11.74M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $10.67M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $9.00M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $5.30M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $5.57M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $6.86M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $7.86M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $6.98M | Mar 30, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.52M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $2.06M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $1.84M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $2.40M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $2.47M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $610.4K | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $1.21M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $3.06M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $4.51M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $4.22M | Mar 30, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.84M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $11.46M | Mar 24, 2026 |
| FY2025 | Dec 31, 2023 | $9.90M | Mar 24, 2026 |
| FY2024 | Dec 31, 2022 | $8.28M | Mar 19, 2025 |
| FY2023 | Dec 31, 2021 | $6.53M | Mar 29, 2024 |
| FY2022 | Dec 31, 2020 | $4.69M | Mar 27, 2023 |
| FY2020 | Sep 30, 2020 | $4.50M | Mar 31, 2021 |
| FY2020 | Jun 30, 2020 | $4.46M | Mar 31, 2021 |
| FY2020 | Mar 31, 2020 | $4.35M | Mar 31, 2021 |
| FY2021 | Dec 31, 2019 | $4.36M | Mar 28, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.46M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $9.21M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $7.77M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $6.30M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $4.77M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $3.06M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $2.75M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $2.19M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $1.68M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $1.10M | Mar 30, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.24M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $2.26M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $3.49M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $4.79M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $4.95M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $1.73M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $1.26M | Mar 31, 2021 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $25.2K | Mar 29, 2017 |
| FY2015 | Dec 31, 2015 | $33.3K | Mar 30, 2016 |
| FY2012 | Dec 31, 2012 | $19.1K | Mar 28, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 28, 2022 |
| FY2020 | Sep 30, 2020 | 0 | Mar 31, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 31, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 31, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 31, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 28, 2022 |
| FY2020 | Sep 30, 2020 | 0 | Mar 31, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 31, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 31, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 31, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4.64M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | 4.64M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | 4.63M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | 4.62M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 4.52M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | 4.51M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | 4.51M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 4.53M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | 4.51M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | 4.51M | Mar 30, 2018 |